Making Medicine

The Making Medicine Podcast, where science, policy, and innovation meet.

[Making Medicine @MakingMedPod]

What if the next breakthrough medicine comes from China?

Should American patients care where it was discovered?

John Stanford and Max Bayer of @endpts examine the ethical questions surrounding proposed COINS Act restrictions.

Check out the full episode on YouTube @MakingMedicinePod

#COINSAct #ChinaBiotech #PatientAccess

[Making Medicine @MakingMedPod]

Treasury's proposed COINS Act rules acknowledge potential risks to U.S. public health and American companies.

What could that mean for biotech investment and patients?

John Stanford and Max Bayer examine the implications on Making Medicine.

Check out the full episode on YouTube @MakingMedicinePod

#COINSAct #BiotechPolicy

[Making Medicine @MakingMedPod]

Treasury says licensing isn't included in its proposed COINS Act rules.
But what about biotech co-development and joint ventures?
Max Bayer of @endpts joins John Stanford on Making Medicine to explain the uncertainty.

Check out the full episode on YouTube @MakingMedicinePod

#COINSAct #ChinaBiotech

[Making Medicine @MakingMedPod]

Slowing China's biotech growth won't automatically strengthen America's.

John Stanford argues that U.S. leadership depends on stronger research, venture investment, entrepreneurship, and FDA modernization.

How should America compete?

#AmericanBiotech #ChinaBiotech

[Making Medicine @MakingMedPod]

Should it matter where a new medicine was first discovered?

John Stanford examines how global biotech partnerships can support American drug development, and why restricting them may have consequences for patients.

#Biotech #Innovation #Biotechnology
@johnbstanford @MedicineMa80739 @incub8coalition @SMMT_TX

[Making Medicine @MakingMedPod]

$120 billion in China biotech deals. But how much has actually been paid?

John Stanford explains why licensing headlines can overstate actual cash flows—and what that means for U.S. biotech policy.

#ChinaBiotech #BiotechInvestment #biotech #innovation #shorts

https://t.co/abtHkL8At8 via @YouTube

@MakingMedPod @MedicineMa80739 @johnbstanford @incub8coalition @FiercePharma @FierceBiotech @FDA @NIH

[Making Medicine @MakingMedPod]

💊Why are so many new medicines unavailable in Japan?

@johnbstanford examines Japan's drug lag, pricing policies, and delayed pharmaceutical launches with @MNakada and @mjgutbrod.

🎙️Watch the episode on YouTube @MakingMedicinePod

@JNJInnovation @incub8coalition @IAmBiotech @MedicineMa80739

#biotech #innovation #sh... https://t.co/Z2jgT4z6VD via @YouTube

[Making Medicine @MakingMedPod]

Could Drug Price Controls Reduce Biotech Investment?

What happens to biotech R&D when drug pricing rules change?

Eddie Pauline explains why he believes government price-setting policies could affect future investment in pharmaceutical innovation.

#biotech #innovation #ohio #mfn

@incub8coalition @johnbstanford @cardinalhealth @LifeSciVC @MakingMedPod @MedicineMa80739

https://t.co/IURlt6lXhP via @YouTube

[Making Medicine @MakingMedPod]

“And we’re behind.”

Eddie Pauline discusses China’s expanding biotech investment and clinical trial capabilities, and the opportunity to strengthen U.S. biotechnology through research hubs like Ohio.

https://t.co/5c465z9LOp via @YouTube

#biotech #innovation #shorts
@johnbstanford @incub8coalition @OSUWexMed @ClevelandClinic @JobsOhio @MedicineMa80739

[Making Medicine @MakingMedPod]

Ohio Has 10% of America’s Gene Therapies?

Ohio isn't just competing for biotech investment. It's building a gene therapy ecosystem.

Eddie Pauline discusses Nationwide Children's role in roughly 10% of FDA-approved gene therapies and why biotech companies are taking notice.

#biotech #innovation #shorts

@OSUWexMed @NCHUrology @cardinalhealth @USGAO @LifeSciVC @NationwideKids @ClevelandClinic @JobsOhio @FDA @johnbstanford @incub8coalition @NIH @MakingMedPod @MedicineMa80739

https://t.co/E3XUK2iJkI via @YouTube